ABSTRACT SUBMISSIONS ARE NOW OPEN!

 

We are delighted to announce that abstract submissions for e-Posters and Oral Communications for ICOM2025 are now open.

 

To be considered for presentation at ICOM2025, it is essential to submit your abstract before 15th March 2025, 23:59 CEST. To ensure a fair and smooth review process, abstracts submitted via e-mail will not be accepted. Therefore, it is essential to adhere to the provided guidelines and use the online submission system to ensure a successful abstract submission.

 

Abstracts may be submitted for Oral Communication Session and e-Poster Presentation. The Scientific Programme Committee will determine whether the abstract will be accepted for presentation, with consideration given to the author’s preference.

 

Accepted authors will be notified of the decision by 31 March 2025.

 

 

Prof. Dr. Timucin Oral Travel Grant

 

The ICOM2025 is offering travel grants to  to help the abstract submitter with the cost of attending the Congress. Submit your Travel Grant application along with your abstract!

 

Rules for submission:

 

Please read the submission rules before submitting an abstract.

 

 

• Abstracts must be submitted online via the website only.

 

• Abstracts submitted by email will not be accepted.

 

• Presentation Type: Abstracts may be submitted for oral communications or e-poster presentation.

 

• The Scientific Committee will determine whether the abstract will be accepted for presentation, with consideration given to the author’s preference.

 

• Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.

 

 

 

 

Limitations:

 

• The same person may submit up to 4 abstracts regardless of presenting author.

 

• The same person may serve as presenting author on up to 4 abstracts.

 

• Presenting authors must be registered participants. Only abstracts of authors who have paid their registration fees by 31st March 2025 will be scheduled for presentation and included for publication.

 

• Submission of an abstract acknowledges your acceptance for the abstract to be published in the official Congress publications.

 

• The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.

 

• Abstracts must be original and must not have been published or presented at any other prior meeting.

 

• All abstracts must be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication

 

• Disclosure of Conflicts of Interest: Abstract submitters will be required to disclose any conflict of interests in the submission form.

 

• Instructions for preparation of presentations will be made available on the congress website.

 

 

 

Guidelines for submission:

 

Before you begin, please prepare the following information:

 

 

• Presenting author’s contact details:

 

• Full first and family name(s)

 

Email address

 

Affiliation details: department, institution / hospital, city, state (if relevant), country

 

Phone number

 

• Author and co-authors’ details

 

• Preferred Presentation type: Oral Communications or E-Poster Presentation.

 

• Abstract title: Title must be in UPPER CASE and limited to 25 words. Please submit symbols as words.

 

• Abstract text: For standardization, the acceptable length of the abstract is limited to 3000 characters and 45 lines, with authors’ details, headers and tables included. This also includes non-visible characters such as spaces as well as punctuation.

 

• Abstract topic: Select the abstract topic per the list of topics.

 

• Images: The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload images in JPG, GIF or PNG format.

 

• Presentation abstracts should be systematically organized into four key sections: Background, Methods, Results, and Discussion. In a similar vein, case reports or case series should follow a structured format that includes: Objective, Case, and Discussion.

 

• Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.

 

• Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.

 

• Submissions may not contain patient names, hospital ID numbers or other identifying information.

 

• Please do not submit multiple copies of the same abstract.

 

Submission system information

 

• Abstracts can be saved in “Draft” status to be re-edited and finalised until the submission deadline. Therefore, the submitter will be required to create a user account.

 

• Abstracts fulfilling all criteria can be saved in “Final submission” status. Only abstracts in “Final submission” status will be regarded as successfully submitted and considered for the congress.

 

• Abstracts in “Final submission” status can be re-edited and modified until the submission deadline.

 

Abstract review

 

• The abstracts will be reviewed by the Local Organising Committee and an experienced panel of reviewers. Following the information regarding acceptance, scheduling information will be sent to the Abstract Submitter.

 

 

Abstract submitters declaration

 

During abstract submission you will be asked to confirm that you agree to the following:

 

• I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published as submitted.

 

• Submission of the abstract constitutes the consent of all authors to publication (e.g. Congress website, programs, other promotions, etc.)

 

• The Abstract Submitter warrants and represents that no part of the information and content provided by him/her (Hereafter: the “Content“) to ICOM2025 and MYEVENT International Organizers of Congresses SA and its affiliates (together: the “Organizers“), nor the publication of any such Content by each of the Organizers, on the internet or otherwise infringes any third party rights, including but not limited to privacy rights and/or intellectual property rights.

 

• The Abstract Submitter grants each of the Organizers the license and right to use, reproduce, publish, translate, distribute, and display the Content or any part thereof, in any manner and on any platform or media whatsoever, in each Organizer’s absolute discretion, on a royalty-free, perpetual, irrevocable nonexclusive basis.

 

• I here with confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract. The submitting author may request to be copied on the abstract correspondence.

 

• I understand that the presenting author must be a registered participant.

 

• The Organizers reserve the right to remove from publication and/or presentation an abstract which does not comply with the above.

 

• I understand that I must select a specific Theme, Topic and/or Sub-Topic for my abstract allocation. Although the Committee will work hard to honour this selection, this cannot be guaranteed. The Committee reserves the right to change the Theme, Topic or Sub-Topic under which the abstract was originally submitted.

 

• I confirm to have received the consent of all authors for the processing of their contact details by MYEVENT and the Organizers.

 

 

Abstracts can be submitted in one of the following topics:

 

• Digital therapy and innovative rehabilitation (Mobile technology, psychoeducation, self-help, information, and communication technologies)

• Lifestyle, exercise, nutrition, nutraceuticals (Omega-3), omplementary therapies

• Artificial intelligence / machine learning

• Big data / mega-analysis projects

• Big consortia - longitudinal projects

• Developmental affective psychopathology (Mood/anxiety disorders in children/adolescents)

• Perinatal affective psychopathology

• Microbiome (Gut and microbiome in mood & anxiety disorders)

• Innovative psychopharmacology

• Psychedelics and rapid acting therapies, ketamine

• Treatment post Covid; Virtual clinics and assessments

• Brain stimulation and physical treatments: rTMS, VNS, DBS, ECT

• Psychiatric/medical/addiction comorbidity in mood & anxiety disorders

• Autoimmune disorders - (neuro-)inflammation in mood & anxiety disorder

• Integration of biological and psychological treatments in mood & anxiety disorders

• Cultural and gender variations in mood & anxiety disorders

• Genetic and pharmacogenetic approaches to mood & anxiety disorders

• Epigenetics, prenatal exposure to stress and mood & anxiety disorders

• Brain structure and function in mood & anxiety disorders

• Service development for mood & anxiety disorders

• Pre-onset identification of mood & anxiety disorders

• Measurement challenges; innovative research designs in mood & anxiety disorders

• Mood and anxiety disorders in the elderly

• Biomarkers for mood & anxiety disorders

• Suicide in mood & anxiety disorders

• Sleep-wake cycle/circadian rhythm disturbances in mood & anxiety disorders

• Patient representation/self-management